# Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

> **NCT02425098** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 351 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- **BIOLOGICAL:** Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

## Key facts

- **NCT ID:** NCT02425098
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-03
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425098, "Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02425098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*